The combination of atezolizumab (Tecentriq), given by injection, and cobimetinib (Cotellic), given orally, is being developed to increase the options available for the treatment of mCRC. This treatment combination will target people that have received at least two previous treatments and did not show any improvements or who initially benefitted but whose disease has since progressed. It is thought that this treatment combination will increase the survival rates for people with mCRC.
Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer - third line
Interventions: Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate)
Indications: Colorectal cancer
Therapeutic Areas: Gastrointestinal Cancer , Oncology